BECOME A CLINICAL TRIAL SITE WITH PFIZER

Clinical trials depend on the experience of healthcare professionals who have dedicated themselves to clinical research. Pfizer is proud to partner with over 6,000 investigators and site staff to conduct our clinical trials around the world. Whether you’re driven by helping patients, advancing medicine, or both, you could help create the next breakthrough.

2021 EAGLE AWARD WINNER

In 2021, the Society for Clinical Research Sites recognized Pfizer with the prestigious Eagle Award for the third year in a row. Voted on by clinical research sites, this award is in recognition of the excellence that we can achieve together with dedicated clinical trial partners like you.

Clinical Trials Are Made Possible By Passionate and Dedicated Professionals

FAQ
- Inflammation & Immunology
  The Inflammation & Immunology development team is dedicated to bringing potential new treatments to patients affected by chronic inflammatory diseases, including alopecia areata, atopic dermatitis, Crohn’s disease, psoriasis, rheumatoid arthritis and ulcerative colitis.
  Learn more about our pipeline.
- Internal Medicine
  The Internal Medicine development team advances innovative medicines that address debilitating and devastating medical challenges impacting large patient populations. Development programs in Internal Medicine are currently underway in diabetes, cardiovascular disease, obesity, cachexia and non-alcoholic steatohepatitis (NASH).
  Learn more about out pipeline.
- Oncology
  The Oncology development team is committed to discovering, investigating, and developing transformative therapies that significantly improve the lives of people with cancer worldwide. Our robust pipeline of novel medicines covers a broad range of cancers. We study these medicines alone and in combination with other treatments to fully explore their ability to change people’s lives.
  Learn more about our pipeline.
- Rare Disease
  The Rare Disease development team helps to develop medicines for people around the world who are suffering from serious illnesses with few or no effective treatment options. Areas of focus include gene therapy, cardiomyopathy, Duchenne muscular dystrophy, growth hormone deficiencies, and hemophilia (A and B).
  Learn more about our pipeline.
- Vaccines
  The Vaccines development team includes an ongoing focus on the prevention of pneumococcal disease, including in adults. We are also advancing vaccines for additional deadly adolescent and adult infections including meningococcal disease, respiratory syncytial virus and Guillain-Barré syndrome.
  Learn more about our pipeline.
- Anti-Infectives
  Current hospital-oriented development programs are directed towards novel anti-infectives to combat antimicrobial resistance.
  Learn more about our pipeline.